Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q9H1P3
UPID:
OSBL2_HUMAN
Alternative names:
-
Alternative UPACC:
Q9H1P3; A8K736; Q6IBT0; Q9BZB1; Q9Y4B8
Background:
Oxysterol-binding protein-related protein 2 (ORP2) plays a pivotal role in intracellular lipid transport, specifically mediating the movement of sterols and phospholipids between cellular compartments. It enhances plasma membrane cholesterol levels while reducing phosphatidylinositol-4,5-bisphosphate, indicating its critical function in lipid homeostasis. ORP2's ability to bind various phosphoinositides and cholesterol derivatives underscores its versatility in lipid interactions.
Therapeutic significance:
ORP2's involvement in autosomal dominant deafness, type 67, highlights its importance in auditory health. This connection suggests that targeting ORP2 could offer new avenues for treating sensorineural hearing loss, emphasizing the need for further research into its therapeutic potential.